Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Gesynta Pharma AB. (4/4/19). "Press Release: Gesynta Pharma Secures 6 MEUR for Development Programs in Financing Round Led by Industrifonden". Solna.

Organisations Organisation Gesynta Pharma AB
  Organisation 2 Industrifonden
  Group Sweden (govt)
Products Product GS-248 (Gesynta Pharma)
  Product 2 venture capital
Index term Index term Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors
Persons Person Brambeck, Jonas (Sweden (govt) 201201 Life Science Investment Manager at Industrifonden before Bruker AB)
  Person 2 Stenberg, Patric (Gesynta Pharma 201904 CEO)
     


Gesynta Pharma AB (“Gesynta”) announces completion of a 6 MEUR financing round, to provide funds for early clinical development of its lead candidate, GS-248. A consortium consisting of venture capital investor Industrifonden and a group of private life sciences investors provides financial and strategic support to Gesynta’s development programs and brings the company to its next pivotal milestone, to make GS-248 ready for Phase II clinical trials in 2020. In connection with the financing round, Gesynta strengthens its board through the addition of non-executive directors Bita Sehat, Investment Manager at Industrifonden, and William Gunnarsson, accomplished life science investor at BWG Invest sarl.

Gesynta’s lead candidate drug, GS-248 is a potent and selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1). GS-248 will elicit its effect through a mechanism that provides combined anti-inflammatory, vasodilatory and platelet inhibitory effects and is being developed for treatment of microvascular diseases in chronic inflammatory conditions.

The investment entails securing 6 MEUR during 2019. In addition to concluding the Phase I clinical program and make GS-248 ready for Phase II, the funds will enable conduct of studies intended for nomination of a candidate drug from Gesynta’s late-stage discovery portfolio that was recently acquired.

“Gesynta has a highly qualified and experienced team and development assets of huge potential. We look forward to the pleasure of working with the company to reach the next levels,” says Jonas Brambeck, Investment Director of Industrifonden.

“We are encouraged to receive support not only from accomplished private life sciences investors, but also from the reputable venture capital investor Industrifonden. The commitment from these investors reflects a firm belief in Gesynta and its therapeutic concept, while also providing the company with funding as well as further competence and investor network.” says Patric Stenberg, CEO of Gesynta Pharma AB.


For further information, please contact:

Gesynta Pharma AB
Patric Stenberg, CEO
Tel: + 46 (0)733 836670
E-mail: patric.stenberg@gesynta.se


About Gesynta Pharma AB

Based on research from Karolinska Institutet, Gesynta leverages expertise in arachidonic acid research to explore the use of mPGES-1 inhibition in cardiovascular diseases and cancer. The clinical candidate, GS-248, is an oral small molecule being developed for the treatment of microvascular disease in chronic inflammatory conditions. When strategically optimal, Gesynta will seek pharma partners to efficiently make the new therapies available to patients and to achieve the full commercial potential of its products. Gesynta is a privately held Swedish company located in Stockholm operating with a team of experts in the fields of mPGES-1 medical research, drug discovery and clinical and business development.

Gesynta is located in the Karolinska Institutet Science Park, Sweden and has received support from Karolinska Institutet Innovations AB, NovoNordisk Foundation, Swelife and Vinnova.

For more information, please visit www.gesynta.se.


About Industrifonden

Industrifonden is one of the Nordic region’s most active investors in the Life Science and Technology areas. Within Life Science, Industrifonden focuses on pharmaceuticals, medical devices and digital health.

For more information, please visit www.industrifonden.com.

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top